Advertisement
TNYA vs VCYT
Which Stock Would AI Choose? Tenaya Therapeutics (TNYA) vs. Veracyte (VCYT) Stock Comparison
Key Takeaways
- TNYA is a pre-revenue, clinical-stage gene-therapy company, while VCYT is a profitable, commercially scaled cancer diagnostics business — a sharp contrast in risk profiles and market positioning.
- Recent sentiment for TNYA has been shaped by a dilutive capital raise and clinical updates, whereas VCYT has reported revenue growth, expanding margins, and positive net income.
- The two names sit in very different market-capitalization and liquidity tiers, making this a comparison of growth-at-a-early-stage risk versus established execution.
- Relative performance diverges meaningfully: VCYT trades at a materially higher share price with institutional breadth, while TNYA remains highly volatile in a low single-digit price range.
- For more detail on each name's latest developments and daily movement, explore TNYA Major News, TNYA Today's Price Move, VCYT Major News, and VCYT Today's Price Move.
- To see how automated strategies are currently positioning across these and thousands of other tickers, visit Trending AI Robots.
Introduction
This stock comparison examines two healthcare names operating at opposite ends of the development spectrum. TNYA (Tenaya Therapeutics) is an early-stage biotechnology company pursuing gene therapies for inherited heart disease, carrying the binary risk and high potential upside typical of pre-commercial drug developers. VCYT (Veracyte) is a profitable diagnostics provider selling genomic cancer tests, with recurring revenue and established reimbursement. Investors weighing speculative, catalyst-driven biotech exposure against steadier, commercially proven healthcare growth may find the contrast useful for understanding relative performance, market positioning, and risk trade-offs in the current environment.
TNYA Overview and Recent Performance
Tenaya Therapeutics is a clinical-stage biotechnology company focused on discovering and developing therapies that address the underlying genetic causes of heart disease. Its lead programs include TN-201, an adeno-associated virus (AAV9)-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (a genetic form of heart muscle thickening), and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), an inherited condition causing irregular heart rhythms.
In recent weeks, sentiment around TNYA has been driven by a mix of regulatory progress and financing pressure. The U.S. Food and Drug Administration (FDA) lifted a clinical hold on the MyPEAK-1 trial of TN-201, allowing dosing to resume, and the company presented interim data from its TN-401 program. At the same time, the company priced a $60 million equity offering of units, which raised capital to extend its cash runway but also introduced meaningful shareholder dilution. As a pre-revenue company with a 52-week trading range in the low single digits per share, the stock has exhibited substantial volatility, with sharp declines accompanying the financing announcement. Analysts have generally maintained Buy ratings, but the company remains dependent on clinical readouts and capital markets.
VCYT Overview and Recent Performance
Veracyte is a global diagnostics company that develops and commercializes genomic tests to guide cancer diagnosis and treatment decisions. Its core franchises include Decipher Prostate, a genomic test for prostate cancer, and Afirma, a test used to evaluate thyroid nodules, alongside a growing presence in bladder and breast cancer testing.
Recent financial results reflect steady execution rather than single-event catalysts. VCYT reported full-year revenue growth in the mid-teens, driven primarily by higher testing volume and average selling prices across its Decipher and Afirma tests, and it posted positive net income for the year while expanding gross and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margins. The company exited the period with a sizable cash balance and no debt. Looking ahead, management has guided to continued double-digit testing revenue growth and highlighted planned product launches, including new tests in minimal residual disease (MRD) and breast cancer. This commercial traction underpins a larger market capitalization and broader institutional ownership relative to TNYA.
Trending AI Robots
Tickeron operates hundreds of AI-powered trading bots that scan and trade thousands of different tickers, each built around distinct strategies, timeframes, and risk parameters. Because market conditions shift constantly, not every bot is equally well suited at any given moment. The Trending AI Robots page curates a selection of the best-performing and most suitable bots for current market conditions, helping traders identify automated approaches with relevant track records and statistics. Bots vary widely in trading style — from short-term momentum to longer-horizon trend-following — and in the sets of tickers they trade. For investors comparing names like TNYA and VCYT, reviewing Trending AI Robots can provide an additional, data-driven lens on relative positioning.
Head-to-Head Comparison
The most fundamental contrast between these companies is stage and revenue model. VCYT generates substantial recurring testing revenue, is profitable, and funds its own operations, giving it a lower-risk, execution-driven profile. TNYA generates no product revenue and relies on equity financing, making it a higher-risk, catalyst-dependent investment where clinical and regulatory outcomes can move the share price sharply.
Growth drivers also differ. VCYT's growth comes from test volume, reimbursement coverage, and new product launches across an expanding oncology footprint. TNYA's value proposition rests on early-stage gene-therapy data and the potential to address diseases with no approved genetic treatments — a larger, more speculative payoff horizon.
Risk factors diverge accordingly. For TNYA, dilution, clinical execution, and cash runway are central concerns. For VCYT, risks center on reimbursement, competition, and the pace of adoption for new tests. Sector exposure is also distinct: cardiovascular gene therapy versus oncology diagnostics. On market sentiment, VCYT benefits from consistent earnings and institutional accumulation, while TNYA sentiment has been more volatile and event-sensitive.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and catalyst structure, Tickeron's AI would likely favor VCYT in the current environment. The stock exhibits more consistent revenue growth, positive profitability, and a steadier fundamental backdrop, which generally aligns with stronger trend and stability signals in automated analysis. TNYA carries meaningful binary catalysts — resumed clinical dosing and upcoming data readouts — that could produce outsized moves, but its pre-revenue status and dilution overhang introduce greater volatility and less predictable positioning. Consequently, the AI is more likely to assess VCYT as the relatively more favorable candidate on a risk-adjusted, probabilistic basis, while recognizing TNYA as a higher-upside, higher-uncertainty alternative.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TNYA is a Hold and VCYT is a Hold.
TNYA sees its Stochastic Oscillator ascends from oversold territory
On November 09, 2026, the Stochastic Oscillator for TNYA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 60 instances where the indicator left the oversold zone. In 53 of the 60 cases the stock moved higher in the following days. This puts the odds of a move higher at over 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TNYA's RSI Indicator exited the oversold zone, 33 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for TNYA just turned positive on October 28, 2026. Looking at past instances where TNYA's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +24.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where TNYA advanced for three days, in 210 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
TNYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TNYA as a result. In 73 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TNYA entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.164) is normal, around the industry mean (3.498). P/E Ratio (-0.706) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (94.340) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. TNYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VCYT sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for VCYT moved below the 200-day moving average on November 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VCYT as a result. In 84 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for VCYT turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 38 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
VCYT moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VCYT crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCYT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCYT advanced for three days, in 205 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
VCYT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.399) is normal, around the industry mean (67.298). P/E Ratio (16.778) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. VCYT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCYT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
VCYT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 75 | |
PRICE GROWTH RATING 1..100 | 88 | |
P/E GROWTH RATING 1..100 | 97 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| TNYA | VCYT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 75% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 75% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Advances ODDS (%) | 6 days ago 86% | 6 days ago 74% |
| Declines ODDS (%) | 12 days ago 90% | 2 days ago 79% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 90% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
TNYA’s FA Score shows that 1 FA rating(s) are green while VCYT’s FA Score has 0 green FA rating(s).
- TNYA’s FA Score: 1 green, 4 red.
- VCYT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
TNYA’s TA Score shows that 5 TA indicator(s) are bullish while VCYT’s TA Score has 4 bullish TA indicator(s).
- TNYA’s TA Score: 5 bullish, 3 bearish.
- VCYT’s TA Score: 4 bullish, 6 bearish.
Price Growth
TNYA (@Biotechnology) experienced а -3.05% price change this week, while VCYT (@Medical Specialties) price change was +0.70% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.79%. For the same industry, the average monthly price growth was -7.29%, and the average quarterly price growth was +34.42%.
Reported Earning Dates
TNYA is expected to report earnings on Mar 23, 2027.
VCYT is expected to report earnings on Mar 01, 2027.
Industries' Descriptions
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (-1.79% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
TNYA and
Correlation & Price change
A.I.dvisor indicates that over the last year, TNYA has been loosely correlated with BNTC. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TNYA jumps, then BNTC could also see price increases.
| Ticker / NAME | Correlation To TNYA | 1D Price Change % | ||
|---|---|---|---|---|
| TNYA | 100% | +0.49% | ||
| BNTC - TNYA | 43% Loosely correlated | -0.55% | ||
| ANIX - TNYA | 43% Loosely correlated | -2.24% | ||
| VCYT - TNYA | 40% Loosely correlated | -1.22% | ||
| SLDB - TNYA | 39% Loosely correlated | -2.29% | ||
| NTLA - TNYA | 36% Loosely correlated | -8.06% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TEI | 6.08 | N/A | N/A |
| Templeton Emerging Markets Income Fund | |||
| KLMT | 34.23 | -0.09 | -0.26% |
| Invesco MSCI Global Climate 500 ETF (KLMT) | |||
| LKOR | 38.47 | -0.13 | -0.33% |
| FlexShares Credit-Scored US Long Corporate Bond Index Fund (LKOR) | |||
| BITA | 51.79 | -1.86 | -3.46% |
| iShares Bitcoin Premium Income ETF (BITA) | |||
| UMAL | 2.00 | -0.24 | -10.71% |
| Defiance Daily Target 2X Long UMAC ETF (UMAL) | |||